# Modification of the dermal matrix by senescence associated lipids and its functional consequence

**Authors:** Sarah Jelleschitz, Christopher Kremslehner, Ionela-Mariana Nagelreiter, Michael Mildner, Melanie Salek, Christina Bauer, Alexandra Stiegler, Adrian Sandgren Fors, Michaela Schirato, Christian Freystätter, Agnès Tessier, Francesca Marcato, Gaëlle Gendronneau, Nada André, Youcef Ben Khalifa, Zhixu Ni, Maria Fedorova, Olga Oskolkova, Marie-Sophie Narzt, Florian Gruber

PMC · DOI: 10.1016/j.redox.2026.104069 · 2026-02-10

## TL;DR

Senescent cells modify collagen in the skin with reactive lipids, causing lasting changes to skin cell behavior and aging.

## Contribution

This study reveals how senescence-associated lipids chemically modify collagen and alter skin cell function and aging.

## Key findings

- Senescent fibroblasts modify collagen via reactive lipids like HNE and OxPL.
- Modified collagen alters fibroblast and macrophage behavior, increasing inflammation and stress responses.
- Lipid-modified collagen in skin models disrupts keratinocyte differentiation and epidermal thickness.

## Abstract

Senescent dermal fibroblasts accumulate and secrete chemically reactive lipids that are components of the senescence-associated secretory phenotype (SASP). These lipids, including 4-hydroxynonenal (HNE) and reactive oxidized phospholipids (OxPL), covalently bind to and modify proteins via Schiff base formation or Michael adduction. Our study examined lipid-induced collagen modifications and their impact on skin cells to evaluate the long-term consequences of senescent cells on the tissue microenvironment. Using mass spectrometry and biochemical analyses, we identified both high and low molecular-weight modifications to collagen types I, II and IV. Collagen modified by HNE reduced fibroblast proliferation and induced stress responses. In contrast, collagen modified by OxPL provoked inflammatory signaling. Both types of modifications influenced matrix remodeling by increasing proteinase expression while reducing collagen expression. Modified collagen also elevated levels of intracellular reactive oxygen species and lipid peroxidation. Macrophages cultured on modified collagen displayed altered cytokine profiles and Toll-like receptor signaling impairment, that depended on the specific type of lipid modification. Similarly, keratinocytes exposed to modified basal lamina collagen IV showed transient stress responses, increased cytokine expression, and reduced matrix metalloproteinase expression. Furthermore, lipid-modified collagen incorporated into organotypic skin equivalents disturbed keratinocyte differentiation and elevated markers of cellular senescence. These skin models also showed reduced epidermal thickness with HNE-modified collagen and parakeratosis on OxPL-modified matrices. In conclusion, the findings suggest that SASP lipids secreted by senescent fibroblasts alter collagen structure and the fate of residing cells. The responses are likely caused by cell-associated oxidation events upon interaction of cells with a lipid-modified matrix and can be inhibited by antioxidants in macrophages. Given collagen's long half-life in tissues, these modifications may represent a persistent mechanism by which senescent cells affect the tissue microenvironment beyond the lifespan of soluble SASP factors ― thereby sustaining an aged phenotype over extended periods.

Graphic created with Procreate (Apple). Illustrative elements adapted from Servier Medical Art (https://smart.servier.com/), licensed under CC BY 4.0.Image 1

•Reactive lipid aldehydes accumulating in and secreted by senescent cells, covalently adduct to the extracellular matrix proteins collagen types I, II, and IV.•Fibroblasts cultured on lipid modified collagen display elevated levels of cytokines, altered matrix turnover and an early senescence phenotype.•Monocyte derived cells grown on modified matrix show altered expression of cyto-/chemokines, elevated senescence markers and impaired pattern recognition receptor signaling.•Organotypic skin equivalents with modified collagen display disturbed epidermal differentiation and elevated expression of senescence markers.

Reactive lipid aldehydes accumulating in and secreted by senescent cells, covalently adduct to the extracellular matrix proteins collagen types I, II, and IV.

Fibroblasts cultured on lipid modified collagen display elevated levels of cytokines, altered matrix turnover and an early senescence phenotype.

Monocyte derived cells grown on modified matrix show altered expression of cyto-/chemokines, elevated senescence markers and impaired pattern recognition receptor signaling.

Organotypic skin equivalents with modified collagen display disturbed epidermal differentiation and elevated expression of senescence markers.

## Linked entities

- **Proteins:** vkg (viking), MMP (matrix metalloproteinase)
- **Chemicals:** 4-hydroxynonenal (PubChem CID 5283344)

## Full-text entities

- **Genes:** ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, B2M (beta-2-microglobulin) [NCBI Gene 567] {aka AMYLD6, IMD43, MHC1D4}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, KRT14 (keratin 14) [NCBI Gene 3861] {aka CK14, EBS1, EBS1A, EBS1B, EBS1C, EBS1D}, COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280] {aka ACG2, ANFH, ANFH1, AOM, COL11A3, EDMMD}, CCR10 (C-C motif chemokine receptor 10) [NCBI Gene 2826] {aka GPR2}, CD14 (CD14 molecule) [NCBI Gene 929], GCLM (glutamate-cysteine ligase modifier subunit) [NCBI Gene 2730] {aka GLCLR}, HSPA4 (heat shock protein family A (Hsp70) member 4) [NCBI Gene 3308] {aka APG-2, HEL-S-5a, HS24/P52, HSPH2, RY, hsp70}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, ALB (albumin) [NCBI Gene 280717], HSPA1A (heat shock protein family A (Hsp70) member 1A) [NCBI Gene 3303] {aka HEL-S-103, HSP70, HSP70-1, HSP70-1A, HSP70-2, HSP70.1}, CHI3L1 (chitinase 3 like 1) [NCBI Gene 1116] {aka ASRT7, CGP-39, GP-39, GP39, HC-gp39, HCGP-3P}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Krt14 (keratin 14) [NCBI Gene 16664] {aka CK-14, K14, Krt-1.14, Krt1-14}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, TLR6 (toll like receptor 6) [NCBI Gene 10333] {aka CD286}, COL17A1 (collagen type XVII alpha 1 chain) [NCBI Gene 1308] {aka BA16H23.2, BP180, BPA-2, BPAG2, ERED, JEB4}, IGFBP2 (insulin like growth factor binding protein 2) [NCBI Gene 3485] {aka IBP2, IGF-BP53}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, KRT10 (keratin 10) [NCBI Gene 3858] {aka BCIE, BIE, CK10, EHK, EHK2, EHK2A}, BSG (basigin (Ok blood group)) [NCBI Gene 682] {aka 5F7, CD147, EMMPRIN, EMPRIN, HAb18G, OK}, ATP6AP2 (ATPase H+ transporting accessory protein 2) [NCBI Gene 10159] {aka (P)RR, APT6M8-9, ATP6IP2, ATP6M8-9, CDG2R, ELDF10}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, LMNB1 (lamin B1) [NCBI Gene 4001] {aka ADLD, LMN, LMN2, LMNB, MCPH26}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, PDPN (podoplanin) [NCBI Gene 10630] {aka AGGRUS, D2-40, GP36, GP40, Gp38, HT1A-1}, S100A9 (S100 calcium binding protein A9) [NCBI Gene 6280] {aka 60B8AG, CAGB, CFAG, CGLB, L1AG, LIAG}, LBP (lipopolysaccharide binding protein) [NCBI Gene 3929] {aka BPIFD2}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, CDK1 (cyclin dependent kinase 1) [NCBI Gene 983] {aka CDC2, CDC28A, P34CDC2}, NTN1 (netrin 1) [NCBI Gene 9423] {aka MRMV4, NET1, NTN1L}, EEF1A1 (eukaryotic translation elongation factor 1 alpha 1) [NCBI Gene 1915] {aka CCS-3, CCS3, EE1A1, EEF-1, EEF1A, EF-Tu}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, Krt10 (keratin 10) [NCBI Gene 16661] {aka D130054E02Rik, K10, K1C1, Krt-1.10, Krt1-10}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, HSP90B2P (heat shock protein 90 beta family member 2, pseudogene) [NCBI Gene 7190] {aka GRP94P1, GRP94b, HSP, HSPCP2, TRA1P1, TRAP1}, H2ax (H2A.X variant histone) [NCBI Gene 15270] {aka H2A.X, H2afx, Hist5-2ax, gammaH2ax}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, ITGA1 (integrin subunit alpha 1) [NCBI Gene 3672] {aka CD49a, VLA1}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, ELANE (elastase, neutrophil expressed) [NCBI Gene 1991] {aka ELA2, GE, HLE, HNE, NE, PMN-E}, TLR3 (toll like receptor 3) [NCBI Gene 7098] {aka CD283, IIAE2, IMD83}, ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59] {aka ACTSA, SMDYS}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, CFD (complement factor D) [NCBI Gene 1675] {aka ADIPSIN, ADN, DF, PFD}, MMRN1 (multimerin 1) [NCBI Gene 22915] {aka ECM, EMILIN4, GPIa*, MMRN}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, CTRL (chymotrypsin like) [NCBI Gene 1506] {aka CTRL1}, TLR5 (toll like receptor 5) [NCBI Gene 7100] {aka MELIOS, SLE1, SLEB1, TIL3}, Lmnb1 (lamin B1) [NCBI Gene 16906], HMOX1 (heme oxygenase 1) [NCBI Gene 3162] {aka HMOX1D, HO-1, HSP32, bK286B10}, HLA-G (major histocompatibility complex, class I, G) [NCBI Gene 3135] {aka MHC-G}
- **Diseases:** CML (MESH:D015464), osteoporosis (MESH:D010024), chronic kidney disease (MESH:D051436), infections (MESH:D007239), cardiovascular diseases (MESH:D002318), diabetes mellitus (MESH:D003920), keratoconus (MESH:D007640), cancer (MESH:D009369), SASP (MESH:D008579), corneal disorder (MESH:D003316), leukemia (MESH:D007938), SE (MESH:D012871), atherosclerosis (MESH:D050197), Inflammation (MESH:D007249), fibrosis (MESH:D005355), PAPC (MESH:C535589), parakeratosis (MESH:D010241), cutis laxa (MESH:D003483), PONPC (MESH:C535298), inflammatory bowel disease (MESH:D015212)
- **Chemicals:** acetonitrile (MESH:C032159), Coomassie Brilliant Blue G-250 (MESH:C004692), amines (MESH:D000588), ketone (MESH:D007659), C (MESH:D002244), phosphatidylcholine (MESH:D010713), hydroimidazolone (MESH:C117197), epinephrin (MESH:D004837), arginine (MESH:D001120), fatty acid (MESH:D005227), DPBS (MESH:C012939), 1-Palmitoyl-2-(9'-oxo-nonanoyl)-sn-glycero-3-phosphocholine (MESH:C097369), thiols (MESH:D013438), Hoechst 33342 (MESH:C017807), Poly(I:C (MESH:D011070), DNPH (MESH:C446799), histidine (MESH:D006639), K2HPO4 (MESH:C013216), PMA (MESH:D013755), MDA (MESH:D015104), amino acid (MESH:D000596), nitrogen (MESH:D009584), formic acid (MESH:C030544), Fibroblast-stimulating Lipopeptide-1 (MESH:C460864), lysophospholipids (MESH:D008246), Phalloidin (MESH:D010590), Hematoxylin (MESH:D006416), BODIPY 581/591C11 undecanoic acid (-), methionine (MESH:D008715), silica gel (MESH:D058428), Paraffin (MESH:D010232), lipofuscin (MESH:D008062), methanol (MESH:D000432), 2,4-Dinitrophenylhydrazine (MESH:C004787), phenol red (MESH:D010637), GlutaMAX (MESH:C054122), d-glucose (MESH:D005947), ethanol (MESH:D000431), formaldehyde (MESH:D005557), DAPI (MESH:C007293), Alexa Fluor 546 (MESH:C481052), NaOH (MESH:D012972), aldehyde (MESH:D000447), Schiff's reagent (MESH:C476677), ROS (MESH:D017382), argon (MESH:D001128), CML (MESH:C048496), KCl (MESH:D011189), lysine (MESH:D008239), Eosin (MESH:D004801), PBS (MESH:D007854), Tween 20 (MESH:D011136), CaCl2 (MESH:D002122), alcohol (MESH:D000438), SDS (MESH:D012967), l-ascorbic acid (MESH:D001205), 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (MESH:C468114), acetic acid (MESH:D019342), 4-hydroxynonenal (MESH:C027576), N-Acetylcysteine (MESH:D000111)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Bos taurus (bovine, species) [taxon 9913]
- **Cell lines:** FSL-1 — Mus musculus (Mouse), Hybridoma (CVCL_C7RB), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006), f42y — Homo sapiens (Human), Hurler syndrome, Induced pluripotent stem cell (CVCL_YC62), M0 — Homo sapiens (Human), Familial hypertrophic cardiomyopathy type 26, Induced pluripotent stem cell (CVCL_A6XE), f37y — Acipenser oxyrinchus (Atlantic sturgeon), Spontaneously immortalized cell line (CVCL_WC97), Fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594)

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12925199/full.md

---
Source: https://tomesphere.com/paper/PMC12925199